Researchers compared COVID-19 outcomes in rheumatoid arthritis patients treated with biologic vs conventional DMARDs.
MedPage Today on MSN
Difficult-to-Treat Rheumatoid Arthritis: Is Prevention Feasible?
CHICAGO -- Hitting rheumatoid arthritis (RA) early and hard, with targeted therapies as first-line treatment, appears to reduce the likelihood that it will reach the dreaded "difficult-to-treat" stage ...
Nonadherence to DMARDs in RA varies widely, with rates from 1.5% to 100% across different studies and DMARD classes. The review identified 31 unique nonadherence measures, with indirect methods like ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback